Key Highlights

  • Park Ha Biological Technology (NASDAQ:BYAH) indicated at USD 2.38 pre-market on November 10, 2026, up 9.16% from a calculated prior close of USD 2.18, a gain of about USD 0.20 per share.
  • With about 3.43 million shares outstanding, the calculated Market Value at USD 2.38 is roughly USD 8.2 million, while trailing Revenue is USD 2.54 million, down 8.1%, and net loss is USD 5.45 million.
  • The 52-week range runs from USD 1.90 to USD 169.40, so the indicated price sits about 98.6% below the high and only 25.3% above the low.
  • Published activity on the stock is limited: the last company items were June 29, July 1 and July 6, 2026 Amazon and trade-group announcements, and law firm notices ran from August 11 to September 21, 2026.

What Moved Park Ha Biological Pre-Market (+9.16%)

Pre-market data on Tuesday, November 10, 2026 show Park Ha Biological Technology (NASDAQ:BYAH) at USD 2.38, up 9.16%. Simple arithmetic gives a calculated prior close of USD 2.18 on Monday, November 9. A published quote page lists a previous close of USD 2.25 and a Volume of 7,995 shares, which does not match the calculated close and likely reflects another session. No company release dated November 9 or November 10, 2026 was found in two searches, so the catalyst is not identified in published coverage. The market value at the indicated price is about USD 8.2 million, using 3.43 million shares. A published page shows market value of USD 8.12 million, down 36.2%.

The Rationale: No Catalyst and General Nano-Cap Mechanics

The latest company announcements were a June 29, 2026 cooperation with Amazon for North American personal care, a July 1 membership application to the Personal Care Products Council and a July 6 approval of its North American Amazon store. Later coverage was Shareholder litigation: a securities class action drew law firm notices on August 11, August 25, August 26 and September 21, with a lead plaintiff deadline of September 28, 2026. General context: with roughly 3.43 million shares, a few thousand shares of buying can move the price by several points of price, and pre-market quotes in nano-caps often reflect a handful of trades rather than a broad shift in demand.

Valuation, Liquidity and Risks

Revenue of USD 2.54 million gives a calculated price to sales ratio near 3.2 at USD 8.2 million market value, while the USD 5.45 million net loss is more than twice sales. The USD 169.40 high against USD 1.90 low shows a collapse of about 98.9% from peak to trough. Volume of 7,995 shares is about 0.2% of shares outstanding, so liquidity is very thin and spreads can be wide. Dilution risk is material for a company with a small float and losses, and Reversal risk is high. The class action adds legal cost and uncertainty. Nothing in this data implies the move will continue.

Where Things Stand

Park Ha Biological Technology (NASDAQ:BYAH) is up 9.16% pre-market on November 10, 2026 with no catalyst identified in published coverage, so the gain most likely reflects thin trading in a nano-cap. The calculated prior close was USD 2.18, the indicated price is USD 2.38, and calculated market value is about USD 8.2 million. The stock sits 25.3% above its USD 1.90 low and 98.6% below its USD 169.40 high. Legal overhang, USD 5.45 million of losses and thin volume keep the risk profile elevated.